Megacap holds up to 8 names from the S&P 500. Selection follows the model's positive score.
Strategy
Equal capital goes into every recommendation. Recommendations are published a few hours before the open and placed as market orders, so buys and sells fill at the opening price. Positions are held for 12 to 17 days. Every position carries a 15% stop-loss: if the price touches it during the day, the position is sold there, at 85% of its entry price. Reported returns are measured from those opening prices and include every stop-loss exit.
CrowdStrike reports fiscal third quarter results after the close on December 1, with management guiding ending ARR to $6.184–6.188 billion and revenue of $1.523–1.529 billion. A clean beat/raise would validate AI-security demand and could reverse recent weakness; a miss on ARR or soft guidance risks further downside given the premium valuation.
AI research citation errors trigger credibility scrutiny
GPTZero flagged citation and factual errors in Accenture-linked AI research papers, including a 2025 agriculture policy report co-produced with IE University. Accenture attributes the errors to human error and plans a corrected release. The issue raises questions about research quality controls as Accenture expands its AI advisory business, a potential modest near-term negative on sentiment.
Accenture is expected to report fiscal Q1 2027 results in December 2026, the first quarter under its 2%-6% local currency growth guide. The report will show how quickly recent record bookings convert to sales and whether the 15.9%-16.1% adjusted margin guide holds amid competitive pricing. This is the dominant near-term catalyst with two-way risk.
FactSet became lead investor and partner in geniosAI to build AI-driven tools for institutional finance, plugging its datasets into geniosAI's LLM platform for portfolio research and risk analysis. The deal supports the AI growth narrative (AI SKUs >10% of new ASV) but adds execution risk amid crowded AI analytics competition.
FactSet reaffirmed FY27 guidance (organic ASV growth 5.0-6.5%, revenue $2,600-2,625M, adjusted EPS $19.25-19.65) and confirmed a regular quarterly dividend. Guidance is described as "higher and tighter" than prior years, though the ASV range represents a declared deceleration from the 7% just delivered, keeping the fair-value debate active.
Mizuho lifted its EPAM price target to $181 from $130 while keeping an Outperform rating, citing three large AI-led deal wins expected to ramp in H1 2027 and AI-native revenue momentum, and raised its 2027 organic constant currency growth expectations. A large PT increase from a credible bank reinforces positive sentiment and can attract incremental buyers.
Piper Sandler sees conservative setup into earnings
Piper Sandler said CrowdStrike has a positive, conservative setup going into its FQ3 report, with the name poised to potentially accelerate and give strong outlooks. Bullish pre-earnings analyst commentary can support sentiment and drive positioning ahead of the December 1 print.
FactSet's first Investor Day under CEO Sanoke Viswanathan outlined a medium-term algorithm of ~6% organic revenue CAGR, at least 36% adjusted operating margin by FY29, ~10% adjusted EPS CAGR, and >90% FCF conversion, while reaffirming FY27 guidance. The FY29 targets came in below consensus and the stock fell ~4% on the day, signaling near-term negative sentiment around decelerating growth.
Continued positive reaction to Q3 and larger buyback
EPAM rose ~4.7% on November 10 as investors continued to digest the strong Q3 profitability, raised outlook, and enlarged repurchase plan with the planned accelerated buyback. Ongoing follow-through buying suggests sustained near-term positive momentum, though it also raises the risk of consolidation after the move.
Following the prior session's surge, TTD shares fell about 6% as the market digested results, with attention on declining profitability and a one-time ~3 percentage point revenue benefit from a strategic partner not expected to recur. The pullback reflects fading post-earnings momentum and could drive near-term volatility.
Mondelez selects Accenture for agentic AI redesign
Mondelez International selected Accenture to redesign its entire Order-to-Cash cycle using agentic AI, linking customer service, supply chain and finance into a single data-driven workflow. The win reinforces Accenture's AI deal momentum and supports positive sentiment around its AI-led growth narrative.
Accenture launches Data-as-a-Service for enterprise AI
Accenture launched Data-as-a-Service, offering industry experts and enterprise testing environments to help organizations train and validate AI for business-critical workflows, alongside the EnterpriseVAL benchmark with Faculty. The launch reinforces Accenture's positioning in enterprise AI and could support positive sentiment.
Cantor Fitzgerald initiates LULU at Neutral, $121 PT
Cantor Fitzgerald initiated coverage with a Neutral rating and $121 price target, with commentary noting the stock struggles to find buyers even at discounted valuation. A cautious initiation limits near-term upside conviction and reinforces resistance at the 50-day moving average.
Sumitomo Mitsui Trust Group reduced its stake by 97.0% in Q3 per its latest 13F, selling 257,511 shares. A large institutional exit can signal waning confidence and add modest selling pressure on sentiment.
Lululemon named Ben Hallam chief brand officer effective November 9 and Emily Sunderland chief strategy officer. The hires could reinforce brand and strategic execution, though no expected financial effects were disclosed, limiting immediate price impact.
Zacks Research upgraded LULU from strong sell to hold, a modest improvement in rating outlook that may marginally ease bearish sentiment but is unlikely to be a major standalone catalyst.
TTD reported Q3 revenue of $736M vs. ~$651M consensus and adjusted EPS of $0.33 vs. $0.25 expected, despite revenue slipping 0.5% YoY. The beat eased growth concerns and triggered a sharp positive reaction, though net income fell 67% YoY and margins compressed, tempering the upside.
The board approved an additional $731M, bringing total available buyback capacity to $1B. The expanded authorization signals management confidence and provides a support mechanism for the stock, contributing to the post-earnings rally.
Management guided Q4 revenue to at least $755M and adjusted EBITDA to at least $280M. The outlook implies continued modest growth but reflects ongoing deceleration, which could cap upside as investors weigh the recovery trajectory.
Netflix integration enables data-driven targeting from November
Netflix expanded its integration with TTD, letting advertisers use first- and third-party data to target audiences via Kokai beginning in November, with in-platform measurement to follow. The expanded CTV access is a potential incremental revenue driver supporting the growth narrative.
Q3 2026 revenue beat and raised full-year guidance
Moderna reported Q3 2026 revenue of $1.3B (+29% YoY), beating the ~$885M consensus by ~48%, with GAAP net income of $162M and diluted EPS of $0.38 versus a year-ago loss. It raised 2026 revenue growth guidance to 15%-25% from up to 10%, cut R&D expense outlook to ~$2.7B, and lifted year-end cash guidance to $8.1-$8.3B. The beat-and-raise is a clear positive near-term catalyst, with shares reportedly jumping on the print.
Intismeran melanoma Phase 3 data shows 42% risk reduction
Moderna and Merck presented positive Phase 3 INTerpath-001 results at ESMO 2026, with intismeran autogene plus KEYTRUDA cutting melanoma recurrence/death risk by 42% (HR=0.58) versus KEYTRUDA alone. The companies are preparing regulatory submissions toward a potential 2027 launch. Continued validation of the personalized cancer vaccine is a key long-term growth driver and supports positive sentiment around the pipeline.
The FDA approved mFLUSIVA, Moderna's mRNA-based seasonal influenza vaccine, for adults 50-64 and accelerated approval for 65+, its fifth approved product globally; Canada approval also received. A limited US launch is planned for the 2026-27 season due to late approval timing, so near-term revenue impact is modest but it broadens the commercial portfolio.
Norovirus vaccine program paused after Phase 3 interim miss
Following a Phase 3 interim analysis that did not meet statistical criteria for early success, Moderna does not plan to initiate an additional cohort this season and will engage health authorities on the program's path forward. The setback removes a near-term pipeline catalyst and is a modest negative offset to the otherwise strong quarter.
mRNA-2808 abstract accepted for ASH oral presentation
Moderna's mRNA-2808 abstract was accepted for an oral presentation at the American Society of Hematology meeting on December 12, 2026 in New Orleans. This is a scheduled near-term data catalyst that could move shares depending on the results disclosed.
Moderna's registrational study for propionic acidemia (mRNA-3927) has reached target enrollment, with pivotal data expected in 2026. An imminent readout represents a binary near-term catalyst for the rare disease pipeline.
Workforce Experience Platform Named Forrester Strong Performer
HP's Workforce Experience Platform was named a Strong Performer in Forrester's Q4 2026 review, earning top scores for roadmap, hybrid work, and digital employee experience. A modest positive for the services narrative ahead of earnings, though likely low direct price impact.
CrowdStrike fell 9.9% on November 5 on nearly triple normal volume, erasing recent gains despite record net new ARR of $333M (+51% YoY). The move reflects a valuation reset and heightened sensitivity to sentiment, leaving the stock reactive to the upcoming earnings catalyst.
Wells Fargo raised its FactSet price target to $290 from $250 on AI-driven data usage but maintained an Underweight rating, citing rising long-term competition as AI lowers barriers to entry. The mixed signal (higher PT, negative rating) offers limited near-term directional support.
EPAM reported Q3 revenue of $1.426B (up 2.3% YoY, 2.5% organic constant currency) and non-GAAP EPS of $3.51, beating the $3.40 consensus, with GAAP operating margin expanding to 12.3% from 10.4%. Full-year revenue growth guidance was raised to 3.5%-3.7% and non-GAAP EPS to $13.23-$13.31. Shares rose ~5% pre-market on the release, and positive follow-through persisted into the following week.
$1.8B buyback authorization and $500M accelerated share repurchase
The Board approved a new $1.8B repurchase program (replacing the prior authorization) and EPAM plans to enter a $500M accelerated share repurchase during the week of November 9, 2026, funded with cash and credit facility borrowings. The company also committed to returning at least 50% of free cash flow to shareholders annually from 2027-2029. The ASR execution is imminent and mechanically supports the stock via reduced share count and confidence signaling.
Investor class action filed; lead plaintiff deadline Jan 4
Pomerantz and other firms publicized a securities fraud class action covering purchases from March 18 to September 3, 2026, alleging the company understated weakening demand before guidance cuts. The pending litigation adds legal and reputational overhang; the lead-plaintiff deadline of January 4, 2027 keeps the issue in the news flow.
HP appointed former GSK CEO and Microsoft board member Emma Walmsley as CEO effective January 4, 2027, with Bruce Broussard moving to Chair. Shares rose 6.6% on the news as investors bet on her restructuring track record to navigate the memory-chip crunch and PC downturn; the positive sentiment may carry into the earnings call.
HP will report fourth-quarter and full-year fiscal 2026 results on November 24, 2026. Investors will focus on Personal Systems profitability, print supplies resilience, AI PC mix (already 46% of shipments), and cost-savings progress amid rising memory-chip costs and mid-single-digit PC unit declines; results and guidance framing are a direct near-term price driver.
Management to Present at UBS Tech Conference Dec 1
HP will attend the UBS Global Technology and AI Conference on December 1, 2026, with Personal Systems President Ketan Patel participating in a fireside chat. Just beyond the two-week window but relevant for post-earnings AI PC messaging and potential incremental commentary.
$495M AI security acquisitions and AI Kill Switch launch
CrowdStrike agreed to acquire Fiddler AI (~$400M) and Dreadnode (~$95M) and launched an AI Kill Switch in Falcon Guardian to terminate rogue AI agents. The strategic AI-security positioning is a positive narrative, though the deals add little near-term revenue and the stock sold off ~10% two days later on valuation concerns.
Baird maintained a Neutral rating with a $115 price target after October checks showed mixed results—low markdown growth, moderating newness growth, and weakening U.S. demand indicators. Checks are consistent with Q3 guidance for Americas revenue down mid-teens, framing a low bar into December earnings but keeping sentiment cautious.